Gary D Novack

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7036998/publications.pdf

Version: 2024-02-01

274 papers	5,463 citations	81900 39 h-index	91884 69 g-index
280 all docs	280 docs citations	280 times ranked	3417 citing authors

#	Article	IF	Citations
1	TFOS DEWS II Report Executive Summary. Ocular Surface, 2017, 15, 802-812.	4.4	502
2	Vitreous Surgery for Macular Holes. Ophthalmology, 1993, 100, 1671-1676.	5.2	353
3	Adherence in Glaucoma: Objective Measurements of Once-Daily and Adjunctive Medication Use. American Journal of Ophthalmology, 2007, 144, 533-540.e2.	3.3	291
4	Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho KinaseÃElevated IOP Treatment Trial 1 and 2 (ROCKET-1 and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.3	190
5	An Objective Evaluation of Eyedrop Instillation in Patients With Glaucoma. JAMA Ophthalmology, 2009, 127, 732.	2.4	186
6	TFOS DEWS II Introduction. Ocular Surface, 2017, 15, 269-275.	4.4	180
7	Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. Journal of AAPOS, 2008, 12, 332-339.	0.3	145
8	Ocular Hypotensive Effect of the Rho Kinase Inhibitor AR-12286 in Patients With Glaucoma and Ocular Hypertension. American Journal of Ophthalmology, 2011, 152, 834-841.e1.	3.3	123
9	Double-masked, Randomized, Doseâ€“Response Study of AR-13324 versus Latanoprost in Patients with Elevated Intraocular Pressure. Ophthalmology, 2015, 122, 302-307.	5.2	120
10	Safety and Efficacy of 2% Pirenzepine Ophthalmic Gel in Children WithMyopia. JAMA Ophthalmology, 2004, 122, 1667.	2.4	112
11	Memory-enhancing effects of post-training dipivefrin and epinephrine: Involvement of peripheral and central adrenergic receptors. Brain Research, 1992, 572, 81-86.	2.2	109
12	Ophthalmic beta-blockers since timolol. Survey of Ophthalmology, 1987, 31, 307-327.	4.0	107
13	Compliance Issues in Manufacturing of Drugs. Ocular Surface, 2003, 1, 80-85.	4.4	99
14	Ocular Pharmacokinetics of Fluocinolone Acetonide After Retisertâ„¢ Intravitreal Implantation in Rabbits Over a 1-Year Period. Journal of Ocular Pharmacology and Therapeutics, 2004, 20, 269-275.	1.4	94
15	A Placebo-controlled, Double-masked Evaluation of Mitomycin C in Combined Glaucoma and Cataract Procedures. Ophthalmology, 1996, 103, 1934-1942.	5.2	92
16	The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 380-386.	1.4	87
17	Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. British Journal of Ophthalmology, 2016, 100, 339-344.	3.9	81
18	A Double-Masked, Randomized, Parallel Comparison of a Fixed Combination of Bimatoprost 0.03%/Timolol 0.5% with Non-Fixed Combination use in Patients with Glaucoma or Ocular Hypertension. European Journal of Ophthalmology, 2007, 17, 53-62.	1.3	80

#	Article	IF	Citations
19	A Single-Blind, Crossover Comparison of the Pharmacokinetics and Cognitive Effects of a New Diazepam Rectal Gel with Intravenous Diazepam. Epilepsia, 1998, 39, 520-526.	5.1	78
20	Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2). American Journal of Ophthalmology, 2019, 200, 130-137.	3.3	78
21	Ophthalmic Drug Delivery: Development and Regulatory Considerations. Clinical Pharmacology and Therapeutics, 2009, 85, 539-543.	4.7	76
22	TFOS DEWS II Clinical Trial Design Report. Ocular Surface, 2017, 15, 629-649.	4.4	73
23	A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. Journal of Allergy and Clinical Immunology, 1998, 102, 251-255.	2.9	67
24	Transconjunctival mitomycin-C in needle revisions of failing filtering blebs. Ophthalmology, 2003, 110, 734-742.	5.2	63
25	Glaucoma Treatment With Once-Daily Levobunolol. American Journal of Ophthalmology, 1986, 101, 298-304.	3.3	62
26	Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5 for postoperative inflammation. Journal of Cataract and Refractive Surgery, 1998, 24, 1480-1489.	1.5	58
27	Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops. Drug Delivery and Translational Research, 2014, 4, 303-309.	5.8	58
28	New Glaucoma Medications in the Geriatric Population: Efficacy and Safety. Journal of the American Geriatrics Society, 2002, 50, 956-962.	2.6	55
29	Cannabinoids for treatment of glaucoma. Current Opinion in Ophthalmology, 2016, 27, 146-150.	2.9	55
30	Trabecular outflow facility determined by fluorophotometry in human subjects. Experimental Eye Research, 1989, 48, 621-625.	2.6	54
31	A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis11None of the investigators had a proprietary interest in loteprednol etabonate.. Ophthalmology, 1999, 106, 362-369.	5.2	53
32	Levobunolol. Ophthalmology, 1985, 92, 1271-1276.	5.2	49
33	Levobunolol Compared With Timolol for the Long-term Control of Elevated Intraocular Pressure. JAMA Ophthalmology, 1985, 103, 379-382.	2.4	45
34	Long-term results of noncontact neodymium:yttriumâ€“aluminumâ€“garnet cyclophotocoagulation in neovascular glaucoma11The authors have no proprietary interest in any of the equipment or materials mentioned in this article.. Ophthalmology, 2003, 110, 895-899.	5.2	45
35	Levobunolol vs Timolol for Open-Angle Glaucoma and Ocular Hypertension. American Journal of Ophthalmology, 1985, 99, 11-17.	3.3	44
36	Epinephrine-induced memory facilitation: attenuation by adrenoceptor antagonists. European Journal of Pharmacology, 1986, 129, 189-193.	3.5	43

#	Article	IF	Citations
37	Change in Intraocular Pressure During Long-Term Use of Loteprednol Etabonate. Journal of Glaucoma, 1998, 7, 266???269.	1.6	42
38	Ocular Hypotensive Safety and Systemic Absorption of AR-13324 Ophthalmic Solution in Normal Volunteers. American Journal of Ophthalmology, 2015, 159, 980-985.e1.	3.3	38
39	The effect of levobunolol on aqueous humor dynamics. Experimental Eye Research, 1987, 44, 49-54.	2.6	36
40	Levobunolol and Betaxolol. Ophthalmology, 1988, 95, 735-741.	5.2	36
41	Pharmacotherapy for the Treatment of Choroidal Neovascularization Due to Age-Related Macular Degeneration. Annual Review of Pharmacology and Toxicology, 2008, 48, 61-78.	9.4	34
42	Ocular pharmacology. Journal of Clinical Pharmacology, 2016, 56, 517-527.	2.0	34
43	Ocular Safety of INS365 Ophthalmic Solution: A P2Y2 Agonist In Healthy Subjects. Journal of Ocular Pharmacology and Therapeutics, 2001, 17, 173-179.	1.4	33
44	Prophylactic Treatment of intraocular Pressure Elevations after Neodymium:YAG Laser Posterior Capsulotomies and Extracapsular Cataract Extractions with Levobunolol. Ophthalmology, 1988, 95, 713-718.	5.2	32
45	A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension*1. Clinical Therapeutics, 2004, 26, 541-551.	2.5	32
46	Levobunolol. JAMA Ophthalmology, 1985, 103, 375.	2.4	30
47	Failure to Detect Systemic Levels, and Effects of Loteprednol Etabonate and its Metabolite, PJ-91, Following Chronic Ocular Administration. Journal of Ocular Pharmacology and Therapeutics, 1998, 14, 153-158.	1.4	29
48	Commercially Available Ocular Hypotensive Products: Preservative Concentration, Stability, Storage, and In-life Utilization. Journal of Glaucoma, 2001, 10, 483-486.	1.6	28
49	New classes of glaucoma medications. Current Opinion in Ophthalmology, 2017, 28, 161-168.	2.9	28
50	A Comparison of the Ocular Hypotensive Efficacy of Once-daily and Twice-daily Levobunolol Treatment. Ophthalmology, 1989, 96, 8-11.	5.2	26
51	Once-daily versus Twice-daily Levobunolol (0.5%) Therapy. Ophthalmology, 1992, 99, 424-429.	5.2	26
52	Randomized, Double-Masked, Placebo-Controlled Study to Assess the Ocular Safety of Mirabegron in Healthy Volunteers. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 674-680.	1.4	26
53	Long-term Evaluation of 0.25% Levobunolol and Timolol for Therapy for Elevated Intraocular Pressure. JAMA Ophthalmology, 1988, 106, 614-618.	2.4	25
54	Effect of Changing Medication Regimens in Glaucoma Patients. Ophthalmologica, 1988, 196, 23-28.	1.9	25

#	Article	IF	Citations
55	Long-term ocular hypotensive effect of levobunolol: results of a one-year study.. British Journal of Ophthalmology, 1985, 69, 593-599.	3.9	24
56	Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers. British Journal of Ophthalmology, 2013, 97, 567-572.	3.9	22
57	Levobunolol compared with timolol: a four-year study.. British Journal of Ophthalmology, 1988, 72, 892-896.	3.9	20
58	Development of responses of globus pallidus and entopeduncular nucleus neurons to stimulation of the caudate nucleus and precruciate cortex. Experimental Neurology, 1979, 66, 479-492.	4.1	19
59	Minimum Concentration of Levobunolol Required To Control Intraocular Pressure in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension. American Journal of Ophthalmology, 1985, 99, 18-22.	3.3	19
60	Flurbiprofen 0.03% for the control of inflammation following cataract extraction by phacoemulsification. Journal of Cataract and Refractive Surgery, 1993, 19, 481-487.	1.5	19
61	The Role of Mitomycin Treatment Duration and Previous Intraocular Surgery on the Success of Trabeculectomy Surgery. Journal of Glaucoma, 1997, 6, 3???9.	1.6	19
62	The Blood-Aqueous and Blood-Brain Barriers to Permeability. American Journal of Ophthalmology, 1988, 105, 412-416.	3.3	18
63	The Role of Pharmaceutical Companies in Sponsored Research. Ophthalmology, 2007, 114, 1037-1038.	5.2	18
64	Repurposing medications. Ocular Surface, 2021, 19, 336-340.	4.4	18
65	Predictive value of muscle relaxant models in rats and cats. Journal of Pharmacological Methods, 1983, 10, 175-183.	0.7	17
66	Ocular Hypotensive Efficacy of 0.25% Levobunolol Instilled Once Daily. Ophthalmology, 1988, 95, 252-255.	5.2	17
67	New pharmacotherapy for the treatment of glaucoma. Expert Opinion on Pharmacotherapy, 2017, 18, 1939-1946.	1.8	17
68	Studies on the efficacy and depressant potential of muscle relaxants in mice. Drug Development Research, 1982, 2, 383-386.	2.9	16
69	Systemic Medications and Glaucoma Patientsâž âžPresented at: American Glaucoma Society meeting, March, 2005; Snowbird, Utah. Study sponsored by Alcon Laboratories, Inc., Fort Worth, Texas. Drs Robin and Novack are consultants to and Mr Covert is an employee of and stockholder in Alcon Laboratories, Inc. Dr Robin is also a consultant to Pfizer and Merck.. Ophthalmology, 2005, 112, 1849.e1-1849.e2.	5.2	15
70	Risks and Benefits. Ocular Surface, 2006, 4, 58-60.	4.4	15
71	Translating Drugs From Animals to Humans: Do We Need to Prove Efficacy?. Translational Vision Science and Technology, 2013, 2, 1.	2.2	15
72	Ocular Drug Delivery Systems Using Contact Lenses. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 595-601.	1.4	15

#	Article	IF	Citations
73	Plasma Levobunolol Levels following Topical Administration with Reference to Systemic Side Effects. Ophthalmologica, 1987, 194, 194-200.	1.9	15
74	Why Aren't There More Pharmacotherapies for Dry Eye?. Ocular Surface, 2014, 12, 227-230.	4.4	13
75	The Right to Try. Ocular Surface, 2015, 13, 88-91.	4.4	13
76	How Much Nonclinical Safety Data Are Required for a Clinical Study in Ophthalmology?. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 5-10.	1.4	13
77	Rho kinase inhibitors for the treatment of glaucoma. Drugs of the Future, 2013, 38, 107.	0.1	13
78	Levobunolol for the long-term treatment of glaucoma. General Pharmacology, 1986, 17, 373-377.	0.7	12
79	New Medical Treatments for Glaucoma. International Ophthalmology Clinics, 1993, 33, 183-202.	0.7	12
80	The â€œIn-betweenâ€•New Drug Application. Ocular Surface, 2009, 7, 53-55.	4.4	12
81	The Accelerated Drug Approval. Ocular Surface, 2010, 8, 205-207.	4.4	12
82	Comparative Irritancy Study among Retinoid Creams and Gels. Journal of Cutaneous Medicine and Surgery, 1999, 3, 298-301.	1.2	11
83	Thoughts Generated by the Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics. Ocular Surface, 2004, 2, 212-214.	4.4	11
84	Caudate neuronal responses evoked by cortical stimulation: contribution of an indirect corticothalamic pathway. Brain Research, 1979, 173, 331-336.	2.2	10
85	Fentanyl: Cumulative effects and development of short-term tolerance. Neuropharmacology, 1978, 17, 77-82.	4.1	9
86	Ocular toxicology. Current Opinion in Ophthalmology, 1997, 8, 88-92.	2.9	9
87	Regression to the Mean. Ocular Surface, 2009, 7, 163-165.	4.4	9
88	Glaucoma Treatment With Once-Daily Levobunolol. American Journal of Ophthalmology, 1987, 104, 443-444.	3.3	8
89	Regulatory review intervals for ophthalmic new drug applications at the US Food and Drug Administration. American Journal of Ophthalmology, 1998, 126, 122-126.	3.3	8
90	What Determines How Much Your Patient Pays for Their Medication in the United States?. American Journal of Ophthalmology, 2016, 167, 48-51.	3.3	8

#	Article	IF	Citations
91	Real world evidence for pharmaceuticals. Ocular Surface, 2019, 17, 584-588.	4.4	8
92	Aqueous Humor, Cerebrospinal Fluid, and Atriopeptin. American Journal of Ophthalmology, 1987, 104, 297-300.	3.3	7
93	Pharmacologic Treatments for Dry Eye. Cornea, 2002, 21, 4-5.	1.7	7
94	Decoding the Packaging Insert: Indications. Ocular Surface, 2003, 1, 150-151.	4.4	7
95	Emerging drugs for ophthalmic diseases. Expert Opinion on Emerging Drugs, 2003, 8, 251-266.	2.4	7
96	The CONSORT Statement for Publication of Controlled Clinical Trials. Ocular Surface, 2004, 2, 45-46.	4.4	7
97	The Importance of A Priori Statistical Planning in Controlled Clinical Trials. American Journal of Ophthalmology, 2015, 160, 4-5.e1.	3.3	7
98	Anticonvulsant effects of benzhydryl piperazines on pentylenetetrazol-induced seizures in mice. Neuropharmacology, 1978, 17, 659-663.	4.1	6
99	Data Monitoring Committees. Ocular Surface, 2010, 8, 40-43.	4.4	6
100	What Does the Food and Drug Administration Safety and Innovation Act Mean For You?. Ocular Surface, 2013, 11, 206-209.	4.4	6
101	Quality of Generic Ophthalmic Drugs. Ocular Surface, 2013, 11, 54-57.	4.4	6
102	Peri-Operative Intracameral Antibiotics: The Perfect Storm?. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 668-671.	1.4	6
103	Clinical Indications for Ophthalmic Corticosteroids. Ocular Surface, 2008, 6, 199-202.	4.4	5
104	What is a New Drug?. Ocular Surface, 2008, 6, 143-146.	4.4	5
105	Treatment Adherence in Ophthalmology and Astrophysics. Ocular Surface, 2010, 8, 91-95.	4.4	5
106	Can I Use Those Eyedrops after the Expiration Date?. Ocular Surface, 2015, 13, 169-173.	4.4	5
107	Chemistry matters!. Ocular Surface, 2017, 15, 264-267.	4.4	5
108	Five variables that rule your life â€“ Home mortgage and biostatistical power. Ocular Surface, 2020, 18, 533-536.	4.4	5

#	Article	IF	Citations
109	Malfunctioning Halothane Vaporizer. Anesthesia and Analgesia, 1981, 60, 121.	2.2	4
110	Excessive Î²-Blockade With Timolol Eye Drops. JAMA - Journal of the American Medical Association, 1996, 275, 985.	7.4	4
111	Financing New Drug Development in Ophthalmology. Journal of Glaucoma, 2000, 9, 195-199.	1.6	4
112	Mechanics of the Food and Drug Administrationâ€™s Form 1571: Investigational New Drug Application. Retina, 2005, 25, S96-S97.	1.7	4
113	Timolol LA: a double-masked, active-controlled, randomized, crossover, comfort, ocular safety, and systemic bioavailability study in healthy volunteers. Current Medical Research and Opinion, 2005, 21, 369-373.	1.9	4
114	Clinical Trial Registryâ€”Update. Ocular Surface, 2009, 7, 212-214.	4.4	4
115	The Development of Drugs vs Devices. Ocular Surface, 2011, 9, 56-58.	4.4	4
116	Where do Unused Medications go When They Die?. Ocular Surface, 2013, 11, 139-142.	4.4	4
117	Some Are More Equal Than Others. Ocular Surface, 2014, 12, 155-158.	4.4	4
118	The â€œTâ€•in JOPT. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 129-129.	1.4	4
119	Product Exclusivity Granted by the U.S. Food and Drug Administration. Ocular Surface, 2016, 14, 74-76.	4.4	4
120	Compared to what? The placebo effect in dry eye therapy. Ocular Surface, 2018, 16, 265-269.	4.4	4
121	A Drug to Prevent Pediatric Myopiaâ€”What Would it Take?. Eye and Contact Lens, 2018, 44, 220-223.	1.6	4
122	FDA review times for new drugs in ophthalmology. Ocular Surface, 2020, 18, 963-966.	4.4	4
123	On Cardiovascular Effects of Topical Glaucoma Therapy [2(2&3):99, 1983]. Cutaneous and Ocular Toxicology, 1984, 3, 243-246.	0.3	3
124	Update on regulatory review intervals for ophthalmic new drug applications at the United States Food and Drug Administration. American Journal of Ophthalmology, 2000, 130, 664-665.	3.3	3
125	How Are Tear Lubricant Products Regulated in the US?. Ocular Surface, 2003, 1, 86.	4.4	3
126	Orphan Drugs. Ocular Surface, 2008, 6, 52-55.	4.4	3

#	Article	IF	Citations
127	Conducting Clinical Trials: Even More Challenges. Ocular Surface, 2008, 6, 99-101.	4.4	3
128	Just a Small, Proof-of-Concept Study. Ocular Surface, 2009, 7, 111-114.	4.4	3
129	Personalized Medicine and the Ocular Surface. Ocular Surface, 2010, 8, 157-160.	4.4	3
130	Withdrawal of Approved Drugs. Ocular Surface, 2011, 9, 111-114.	4.4	3
131	Time to Take Your Medicines, Seriously. Ocular Surface, 2016, 14, 410-415.	4.4	3
132	Generally Regarded As Safe. Ocular Surface, 2017, 15, 152-155.	4.4	3
133	Retinal Detachment: Patient Perspective and Electronic Health Records. American Journal of Ophthalmology, 2019, 208, 64-67.	3.3	3
134	How many vs. how much. Ocular Surface, 2019, 17, 167-171.	4.4	3
135	The Development of New Drugs for Ophthalmology. American Journal of Ophthalmology, 1992, 114, 357-364.	3.3	2
136	Industrial publication of controlled clinical trial data. Clinical Pharmacology and Therapeutics, 1993, 53, 495-496.	4.7	2
137	Ophthalmic Drug Development. Journal of Glaucoma, 1998, 7, 202???209.	1.6	2
138	Dear Dr. Walson. Clinical Therapeutics, 2002, 24, 1477-1478.	2.5	2
139	Eyes on New Product Development: Ophthalmic Drug Delivery. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 90-91.	1.4	2
140	Eyes on New Product Development: Trabecular Meshwork. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 83-84.	1.4	2
141	Investing in New Therapies for Ocular SurfaceÂDisease. Ocular Surface, 2015, 13, 263-267.	4.4	2
142	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 445-446.	1.4	2
143	Do Genes Matter in Treating Eye Disease?. Ocular Surface, 2015, 13, 346-349.	4.4	2
144	Ocular Hypotensive Medications. , 2015, , 521-524.		2

#	Article	IF	Citations
145	Efficacy and safety of netarsudil 0.02% ophthalmic solution in patients with open-angle glaucoma and ocular hypertension. Expert Review of Ophthalmology, 2019, 14, 191-197.	0.6	2
146	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 1-2.	1.4	2
147	Keeping up with current science --- how much is enough?. Ocular Surface, 2020, 18, 186-189.	4.4	2
148	Off-Label Use as a Standard of Care. American Journal of Ophthalmology, 2021, 224, A6-A8.	3.3	2
149	What is an adequate and well controlled study?. Ocular Surface, 2021, 20, 215-218.	4.4	2
150	Unapproved drugs â€“ A fix to an unintended consequence of an FDA policy. Ocular Surface, 2021, 21, 351-354.	4.4	2
151	N-of-1 Clinical Trials: A Scientific Approach to Personalized Medicine for Patients with Rare Retinal Diseases Such as Retinitis Pigmentosa. Journal of Ocular Pharmacology and Therapeutics, 2021, 37, 495-501.	1.4	2
152	Compounded medications for ocular surface disease. Ocular Surface, 2021, 22, 267-270.	4.4	2
153	Flurazepam and triazolam: Dose-response and time-response evaluation on cat sleep. Electroencephalography and Clinical Neurophysiology, 1984, 57, 277-288.	0.3	1
154	Effect of changing beta-blocker treatment in six patients allergic to timolol. Cutaneous and Ocular Toxicology, 1987, 6, 179-181.	0.3	1
155	The Effect of Twice Daily Nadolol on Intraocular Pressure. American Journal of Ophthalmology, 1988, 105, 435-436.	3.3	1
156	Decoding the Package Insert: Adverse Events. Ocular Surface, 2003, 1, 202-203.	4.4	1
157	What Does It Mean When a Company Says That a Product Is â€œApprovableâ€?. Ocular Surface, 2005, 3, 63-64.	4.4	1
158	Should You Be a Clinical Investigator for a New Pharmaceutical?. Ocular Surface, 2005, 3, 168-170.	4.4	1
159	Research Ethics. Ocular Surface, 2006, 4, 103-106.	4.4	1
160	Pharmacotherapy: How Much Drug Is There?. Ocular Surface, 2007, 5, 58-61.	4.4	1
161	Timolol Concentrations in Breast Milk of a Woman Treated for Glaucoma: Calculation of Neonatal Exposure. Journal of Glaucoma, 2008, 17, 510.	1.6	1
162	Drop Size: An Issue Wrapped in a Non-Issue Wrapped in an Issue. Ocular Surface, 2011, 9, 185-188.	4.4	1

#	Article	IF	Citations
163	Stephen Jay Gould and Statistics, 2011 Version. Ocular Surface, 2011, 9, 239-241.	4.4	1
164	Drug Shortages. Ocular Surface, 2012, 10, 51-54.	4.4	1
165	How Do Drugs Get Their Brand Names?. Ocular Surface, 2012, 10, 117-120.	4.4	1
166	How Should We Display Our Data? What Is the Best Number?. Ocular Surface, 2012, 10, 193-198.	4.4	1
167	The Benefit/Risk of Good Therapeutics. Ocular Surface, 2012, 10, 264-266.	4.4	1
168	Fill Size for Ophthalmic Products. Ocular Surface, 2013, 11, 285-287.	4.4	1
169	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 2-3.	1.4	1
170	Confusion in Product Packaging. Ocular Surface, 2014, 12, 77-81.	4.4	1
171	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 130-130.	1.4	1
172	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 1-2.	1.4	1
173	Unapproved Ophthalmic Drugs. Ocular Surface, 2016, 14, 317-320.	4.4	1
174	Natural Does Not Mean Safe. Ocular Surface, 2016, 14, 515-519.	4.4	1
175	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 401-402.	1.4	1
176	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 65-65.	1.4	1
177	Slit Lamp-Based Ocular Scoring Systems: Commentary. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 237-238.	1.4	1
178	Thoughts on improving medication use. Ocular Surface, 2018, 16, 191-195.	4.4	1
179	How a drug developer thinks about a new ophthalmic product. Ocular Surface, 2018, 16, 390-392.	4.4	1
180	Recent milestone U.S. ophthalmic product approvals and clearances. Ocular Surface, 2018, 16, 487-491.	4.4	1

#	Article	IF	Citations
181	Regulatory and Developmental Aspects of Biomarkers in the Treatment of Ocular Surface Disease. Eye and Contact Lens, 2020, 46, S106-S108.	1.6	1
182	The clinical trial outline. Contemporary Clinical Trials, 1984, 5, 311.	1.9	0
183	Glaucoma Treatment with Once-Daily Levobunolol: Reply. American Journal of Ophthalmology, 1986, 102, 546-547.	3.3	0
184	Randomized Clinical Trials on Medical Treatment of Glaucoma: Are They Appropriate to Guide Clinical Practice?. JAMA Ophthalmology, 1994, 112, 726.	2.4	0
185	Pupillary response to four concentrations of pilocarpine in normal subjects. American Journal of Ophthalmology, 2003, 135, 259-260.	3.3	0
186	Fluorometholone in children. Ophthalmology, 2003, 110, 1072-1073.	5.2	0
187	What Happens to Patients at the End of the Clinical Trial?. Ocular Surface, 2004, 2, 267-269.	4.4	0
188	Development of Topical Agents. Ocular Surface, 2004, 2, 166-168.	4.4	0
189	Is the World Flat for Pharmaceuticals?. Ocular Surface, 2005, 3, 212-214.	4.4	0
190	Adaptive Trials. Ocular Surface, 2006, 4, 215-217.	4.4	0
191	Glaucoma and Intravitreal Steroids. Ophthalmology, 2006, 113, 1688-1688.	5.2	0
192	Clinical Trial Registration. Ocular Surface, 2007, 5, 316-317.	4.4	0
193	Notification vs Approval. Ocular Surface, 2007, 5, 255-258.	4.4	0
194	Authorship Policy. American Journal of Ophthalmology, 2009, 147, 184.	3.3	0
195	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2012, 28, 557-558.	1.4	0
196	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 1-2.	1.4	0
197	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 449-449.	1.4	0
198	New Pharmacological Treatments for Dry Eye Disease. Current Ophthalmology Reports, 2013, 1, 75-79.	1.2	0

#	Article	IF	Citations
199	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 513-514.	1.4	0
200	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 611-611.	1.4	0
201	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 701-701.	1.4	0
202	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 785-785.	1.4	0
203	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 379-379.	1.4	0
204	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 843-843.	1.4	0
205	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 603-604.	1.4	0
206	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 525-526.	1.4	0
207	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 371-372.	1.4	0
208	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 301-302.	1.4	0
209	Phases of Clinical Development. Ocular Surface, 2014, 12, 307-311.	4.4	0
210	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 799-799.	1.4	0
211	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 445-446.	1.4	0
212	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 687-687.	1.4	0
213	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 587-588.	1.4	0
214	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 311-313.	1.4	0
215	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 61-62.	1.4	0
216	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 187-188.	1.4	0

#	Article	IF	Citations
217	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 363-364.	1.4	0
218	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 257-257.	1.4	0
219	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 1-1.	1.4	0
220	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 509-510.	1.4	0
221	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 185-185.	1.4	0
222	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 133-134.	1.4	0
223	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 238-239.	1.4	0
224	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 483-483.	1.4	0
225	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 563-564.	1.4	0
226	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 341-342.	1.4	0
227	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 639-639.	1.4	0
228	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 65-66.	1.4	0
229	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 1-2.	1.4	0
230	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 129-131.	1.4	0
231	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 214-215.	1.4	0
232	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 705-706.	1.4	0
233	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 573-573.	1.4	0
234	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 645-646.	1.4	0

#	Article	IF	Citations
235	Anti-science in the 21st century. Ocular Surface, 2017, 15, 813-819.	4.4	0
236	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 499-500.	1.4	0
237	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 423-425.	1.4	0
238	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 335-336.	1.4	0
239	Eyes on New Product Development: Preclinical Research. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 311-311.	1.4	0
240	Eyes on New Product Development: Preclinical Research. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 4-6.	1.4	0
241	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 233-234.	1.4	0
242	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 555-556.	1.4	0
243	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 657-658.	1.4	0
244	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 603-604.	1.4	0
245	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 487-488.	1.4	0
246	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 373-373.	1.4	0
247	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 427-428.	1.4	0
248	Re: â€œPharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyesâ€•by Sekine et al.(J. Ocul. Pharmacol. Ther. 2018;34:280â€“286). Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 429-430.	1.4	0
249	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 319-321.	1.4	0
250	Collaboration or competition: Take your pick. Ocular Surface, 2019, 17, 833-837.	4.4	0
251	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 421-422.	1.4	0
252	Treatment Duration and Side Effect Profile of Long-term Use of Intravitreal Preservative-free Triamcinolone Acetonide in Uveitis. American Journal of Ophthalmology, 2019, 202, 151.	3.3	0

#	Article	IF	Citations
253	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 77-78.	1.4	0
254	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 263-264.	1.4	0
255	Re: Rosenfeld etÂal.: Lessons from recent phase III trial failures: don't design phase III trials based on retrospective subgroup analyses from phase II trials (Ophthalmology. 2018;125:1488-1491). Ophthalmology, 2019, 126, e31-e32.	5.2	0
256	Calculus and tear flow. Ocular Surface, 2019, 17, 365-368.	4.4	0
257	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 201-202.	1.4	0
258	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 137-137.	1.4	0
259	Regulatory Requirements for Cell-Based Therapy for Degenerative Retinal Disease. Pancreatic Islet Biology, 2019, , 97-107.	0.3	0
260	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 267-268.	1.4	0
261	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 199-200.	1.4	0
262	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 73-74.	1.4	0
263	Treating ocular surface disease â€“ A daily experience. Ocular Surface, 2020, 18, 345-348.	4.4	0
264	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 135-136.	1.4	0
265	Eyes on New Product Development: Regulations, Generics, and Disruptive Technologies. Journal of Ocular Pharmacology and Therapeutics, 2021, 37, 249-250.	1.4	0
266	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2021, 37, 383-385.	1.4	0
267	Drug Development Issues in Pharmacological Treatments for Dry Eye. Advances in Experimental Medicine and Biology, 2002, 506, 1117-1120.	1.6	0
268	Intraocular Pressure and Visual Field Damage as Risk Factors for Visual Field Progression in Filtering Surgery. Ophthalmic Surgery Lasers and Imaging Retina, 2010, 41, 452-458.	0.7	0
269	Calculating efficacy of new ophthalmic treatments. The new calculus. Ocular Surface, 2022, 23, 219-223.	4.4	0
270	Schlenker etÂal.: How mean intraocular pressures are failing patients (Ophthalmology Glaucoma.) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.9	0

#	Article	IF	Citations
271	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2022, , .	1.4	0
272	Eyes on New Product Development. Journal of Ocular Pharmacology and Therapeutics, 2022, 38, 201-202.	1.4	0
273	Expedited regulatory product approval in the time of COVID-19. Ocular Surface, 2022, , .	4.4	0
274	Eyes on New Product Development: Long-Acting Ocular Drug Delivery Technologies Addressing Unmet Needs in Ophthalmology. Journal of Ocular Pharmacology and Therapeutics, 0, , .	1.4	0